MOTS-c Research Overview (also known as Mitochondrial ORF of the 12S rRNA type-c peptide, MOTS-c, Humanin-related peptide)
A 16-amino acid peptide encoded within mitochondrial DNA, classified as a mitochondrial-derived peptide (MDP). Activates AMPK, improving glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Circulating MOTS-c rises approximately 1.5-fold during exercise in humans, earning it the label of an 'exercise mimetic.'
Researchers examining mitochondrial signaling may also wish to review Klotho, a longevity-associated protein studied in related aging and metabolic contexts.
For the regulatory discussion specific to MOTS-c and other compounds considered by the FDA advisory panel, read FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding.
What Is MOTS-c?
MOTS-c (Mitochondrial-derived peptide c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome — a member of the mitochondrial-derived peptides (MDPs), a recently discovered class of mitochondria-encoded hormones. Discovered in 2015, MOTS-c acts as a mitochondria-to-nucleus retrograde signaling molecule that regulates nuclear gene expression in response to metabolic demand.
Mechanism of Action
MOTS-c translocates from mitochondria to the nucleus, where it regulates transcription of genes involved in metabolic adaptation — particularly those in the folate cycle and methionine metabolism pathways. It also activates AMPK (AMP-activated protein kinase) — the master metabolic regulator — contributing to enhanced insulin sensitivity, increased fatty acid oxidation, and reduced hepatic glucose production. These effects collectively mimic exercise adaptations at the molecular level.
Exercise Mimicry and Longevity
MOTS-c levels rise in response to exercise, and administration in aged or obese mice produces striking improvements: reversed insulin resistance, reduced fat accumulation, and dramatically enhanced exercise tolerance. MOTS-c levels decline with age, and genetic variants in the MOTS-c-encoding region of the mitochondrial genome correlate with longevity in multiple human population studies — making it one of the most promising aging biology research targets currently under investigation.
Quick Reference
| Literature-Reported Dose Range | 1–3 mg daily or 3–5 mg 3× weekly |
| Literature-Reported Frequency | Once daily or 3x weekly |
| Literature-Reported Cycle Length | 4-12 weeks |
| Literature-Reported Washout | 2-4 weeks |
| Storage | Lyophilized: room temp 3 weeks or freezer. Reconstituted: 2-8°C for 14 days |
| Sites Reported in Studies | Subcutaneous: abdomen, thigh, upper arm |
| Timing | Morning before exercise |
Research Indications
Metabolic
Insulin Resistance
Improves insulin sensitivity by ~30% through AMPK activation. Enhances glucose uptake in skeletal muscle.
Type 2 Diabetes
Improves glucose homeostasis through enhanced insulin receptor sensitization and AMPK-mediated regulation.
Obesity Prevention
Prevents obesity despite identical caloric intake. Promotes fatty acid oxidation and thermogenesis.
Anti-Aging
Physical Performance
Reverses age-dependent physical decline. Improves grip strength and exercise capacity in aged animals.
Mitochondrial Function
Enhances mitochondrial biogenesis and respiratory capacity through PGC-1α activation.
Longevity
Late-life treatment showed 6.4% lifespan extension in mice. 21% age-related decline in humans.
Exercise Performance
Exercise Capacity
Single dose improved running performance by 12-15%. Exercise induces 11.9-fold increase in muscle MOTS-c.
Muscle Homeostasis
Supports muscle health through myostatin reduction. Positively correlated with muscle strength.
Recovery
Promotes mitochondrial biogenesis and reduces inflammation for improved recovery.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Metabolic health | 5-10mg | Once daily | SubQ |
| Anti-aging protocol | 15mg | 3x weekly | SubQ |
| Exercise performance | 1–3 mg daily or 3–5 mg 3× weekly | Pre-workout | SubQ |
| Conservative start | 5mg | Once daily | SubQ |
Timing
Recommended administration window: morning before exercise. Typical onset: aMPK activation 30 min, glucose improvements 1-2 weeks, full benefits 4-8 weeks.
Peptide Interactions
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
Both activate AMPK pathway - may cause additive hypoglycemic effects. Monitor blood glucose closely.
Complementary mitochondrial enhancement through different pathways. May amplify metabolic and anti-aging benefits.
Different mechanisms allow safe combination with potential synergistic metabolic benefits.
Both are AMPK activators with potential for additive glucose-lowering effects.
Complementary SIRT1/AMPK activation may enhance longevity and metabolic benefits.
Enhanced insulin sensitivity may require dose adjustments to prevent hypoglycemia.
Reported Research Timeline
01Week 1–2 (reported in cited studies): aMPK activation, initial glucose improvements
02Week 2–4 (reported in cited studies): enhanced exercise capacity, improved insulin sensitivity
03Week 4–8 (reported in cited studies): sustained metabolic benefits, body composition improvements
04Week 8–12 (reported in cited studies): maximum mitochondrial function enhancement
Side effects (reported in cited studies): generally mild, possible injection site reactions
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated with minimal side effects
Monitor blood glucose if using diabetes medications
Limited long-term human safety data
May cause mild injection site reactions
Not recommended during pregnancy or breastfeeding
WADA prohibited substance for athletes
Seek Medical Attention If:
Severe allergic reactions or anaphylaxis
Recurrent hypoglycemia (<50 mg/dL)
Persistent severe injection site reactions
Unexplained weight loss >10%
Any concerning symptoms - consult healthcare provider
Quality Indicators
Verified Marker
White to Off-White Powder
Uniform appearance without discoloration indicates proper storage and purity >95%.
Verified Marker
Clear Solution After Reconstitution
Should be colorless and clear without particles or cloudiness.
Verified Marker
Sequence Verification
Confirm sequence is MRWQEMGYIFYPRKLR with Certificate of Analysis showing >95% purity.
Acceptable Range
Limited Human Data
Start with conservative doses (5-10mg) due to limited clinical safety data.
Quality Concern
No FDA Approval
Not FDA-approved for human use. Available only as research peptide.
Quality Concern
WADA Banned Substance
Prohibited by WADA as AMPK activator for athletic performance enhancement.
Research Citations
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee, C., Zeng, J., Drew, B.G., et al., Cohen, P., 2015, Cell Metabolism - MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds, J.C., Lai, R.W., Woodhead, J.S.T., et al., Lee, C., 2021, Nature Communications - The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
Kim, K.H., Son, J.M., Benayoun, B.A., Lee, C., 2018, Cell Metabolism - MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose
Hyatt, J.P., et al., 2022, Physiological Reports - The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus
Yin, X., et al., 2022, Pharmacological Research - Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction
Qin, Q., Delrio, S., Wan, J., et al., Lerman, A., 2018, International Journal of Cardiology - Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
Wan, W., Zhang, L., Lin, Y., et al., Ying, J., 2023, Journal of Translational Medicine - MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
Mohtashami, Z., Singh, M.K., Salimiaghdam, N., et al., Kenney, M.C., 2022, International Journal of Molecular Sciences - MOTS-c Serum Concentration Positively Correlates with Lower-Body Muscle Strength and Is Not Related to Maximal Oxygen Uptake
Domin, R., Pytka, M., Żołyński, M., et al., Ruchała, M., 2023, International Journal of Molecular Sciences - Exploring the therapeutic potential of MOTS-c in age-related macular degeneration: from cellular responses to patient-derived cybrids
Mohtashami, Z., Schneider, K., Azimi, R., et al., Singh, M.K., 2025, Human Cell - MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis
Yang, L., Li, M., Liu, Y., et al., Liu, S., 2024, Acta Biochimica et Biophysica Sinica
Research Focus
Mitochondrial signaling, Insulin sensitivity, Exercise mimicry, Longevity, Metabolic health, AMPK activation
Verified Vendors Carrying MOTS-c
Frequently Asked Questions
What should researchers watch for with MOTS-c?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with MOTS-c?
Week 1–2 (reported in cited studies): aMPK activation, initial glucose improvements
How is MOTS-c typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →